MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%
Sector Heatmap
Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%
ALGS — Aligos Therapeutics, Inc. Common Stock
NasdaqAligos Therapeutics, Inc. Common Stock
$5.50
-0.13(-2.31%)
- O
- 5.69
- H
- 5.74
- L
- 5.37
- V
- 28.26K
⏱️ End-of-day dataAs of Oct 1, 2026
Chart
About ALGS
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateOct 16, 2020
Employees82
Stock ExchangeNasdaq
Ticker SymbolALGS
Websitehttps://www.aligos.com
Key Financial Statistics
| Market Cap | $34.41M |
| P/E Ratio | N/A |
| Dividend Yield | N/A |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $3.76 - $937.75 |
| 52-Week Avg Volume | 66.2K |
| VWAP | $5.60 |
| Transactions | 800 |
| Total Recorded Bars | 1,496 days |